Payment overview · 2025
General Payments
$75.22
4 reported records · 2 companies
Healthcare provider profile · identity verified
John Prokop, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · BELPRE, OH · NPI 1396108676
Verified facts
What the public records show
CMS Open Payments records show John Prokop, D.O. received $75.22 in general payments during 2025 across 4 reported records.
ABBVIE INC. accounted for 75.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Prolia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56.55 | 75.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.67 | 24.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $75.22 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $40.77 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $40.77 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
93 | 25 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 592 | 182 |
| Losartan Potassium | Losartan Potassium | 489 | 142 |
| Amlodipine Besylate | Amlodipine Besylate | 410 | 123 |
| Levothyroxine Sodium | Levothyroxine Sodium | 402 | 124 |
| Gabapentin | Gabapentin | 362 | 101 |
| Pantoprazole Sodium | Pantoprazole Sodium | 348 | 115 |
| Hydrochlorothiazide | Hydrochlorothiazide | 259 | 83 |
| Lisinopril | Lisinopril | 253 | 75 |
| Omeprazole | Omeprazole | 248 | 79 |
| Metoprolol Tartrate | Metoprolol Tartrate | 245 | 85 |
| Metformin Hcl | Metformin Hcl | 228 | 72 |
| Furosemide | Furosemide | 201 | 66 |
| Eliquis | Apixaban | 199 | 45 |
| Sertraline Hcl | Sertraline Hcl | 199 | 64 |
| Trazodone Hcl | Trazodone Hcl | 199 | 64 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 196 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 192 | 64 |
| Potassium Chloride | Potassium Chloride | 191 | 64 |
| Clopidogrel | Clopidogrel Bisulfate | 174 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 171 | 56 |
| Lorazepam | Lorazepam | 157 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 145 | 45 |
| Glimepiride | Glimepiride | 141 | 43 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 140 | 34 |
| Simvastatin | Simvastatin | 139 | 44 |
| Meloxicam | Meloxicam | 131 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 129 | 34 |
| Montelukast Sodium | Montelukast Sodium | 126 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 125 | 57 |
| Pravastatin Sodium | Pravastatin Sodium | 119 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 109 | 39 |
| Allopurinol | Allopurinol | 108 | 36 |
| Tramadol Hcl | Tramadol Hcl | 108 | 29 |
| Alprazolam | Alprazolam | 106 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 104 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 102 | 31 |
| Pregabalin | Pregabalin | 102 | 20 |
| Metformin Hcl Er | Metformin Hcl | 97 | 30 |
| Ezetimibe | Ezetimibe | 94 | 32 |
| Prednisone | Prednisone | 94 | 77 |
| Lovastatin | Lovastatin | 93 | 25 |
| Synthroid | Levothyroxine Sodium | 93 | 25 |
| Famotidine | Famotidine | 82 | 30 |
| Jardiance | Empagliflozin | 79 | 26 |
| Alendronate Sodium | Alendronate Sodium | 76 | 33 |
| Doxycycline Hyclate | Doxycycline Hyclate | 76 | 66 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 72 | 16 |
| Cephalexin | Cephalexin | 70 | 58 |
| Ozempic | Semaglutide | 68 | 16 |
| Trulicity | Dulaglutide | 66 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 61 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 60 | 19 |
| Carvedilol | Carvedilol | 60 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 18 |
| Celecoxib | Celecoxib | 54 | 18 |
| Warfarin Sodium | Warfarin Sodium | 54 | 14 |
| Mirtazapine | Mirtazapine | 53 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | 16 |
| Buspirone Hcl | Buspirone Hcl | 50 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 50 | 11 |
| Spironolactone | Spironolactone | 50 | 18 |
| Sucralfate | Sucralfate | 50 | 27 |
| Clonazepam | Clonazepam | 49 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 48 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | 14 |
| Fluconazole | Fluconazole | 45 | 31 |
| Ibuprofen | Ibuprofen | 44 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 40 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 34 |
| Atenolol | Atenolol | 38 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 12 |
| Enalapril Maleate | Enalapril Maleate | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 19 |
| Valsartan | Valsartan | 32 | suppressed |
| Nystatin | Nystatin | 31 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 31 | 13 |
| Nitroglycerin | Nitroglycerin | 30 | 15 |
| Estradiol | Estradiol | 28 | 11 |
| Finasteride | Finasteride | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | 12 |
| Repatha Sureclick | Evolocumab | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 19 |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 24 |
| Linzess | Linaclotide | 25 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | 13 |
| Temazepam | Temazepam | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | 12 |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 15 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Admelog Solostar | Insulin Lispro | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | 12 |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Takhzyro | Lanadelumab-Flyo | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $75.22 · 4 records | ABBVIE INC. | CREON, EVENITY, LINZESS, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error